Trials / Completed
CompletedNCT05594875
A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors
An Open-Label, Multi-Center Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-1921.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1921 | Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-04-24
- Completion
- 2024-04-24
- First posted
- 2022-10-26
- Last updated
- 2024-06-25
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05594875. Inclusion in this directory is not an endorsement.